GlaxoSmithKline announces positive data from Harmony 8 study

GlaxoSmithKline has received encouraging data from its Harmony 8 test, a 52-week randomised study comparing albiglutide to a DPP-4 inhibitor, sitagliptin, in type 2 diabetes patients with renal impairment.

The information gained from the test will allow the company to complete its clinical registration for the new treatment, with plans to finish the chemistry and manufacturing package in the coming months.

Global regulatory submissions for albiglutide are to be sent off in early 2013, the firm claimed.

This is the first full study of the efficacy and safety of a GLP-1 agonist on patients with mild to severe renal problems and could have a serious effect on how patients with type 2 diabetes are treated.

"Detailed analysis of the full data set from Harmony 8 and the cardiovascular meta-analysis will be conducted in the coming months," the company explained.

GlaxoSmithKline recently revealed positive clinical trial data for the once-daily HIV treatment dolutegravir.